Valuation: DaShenLin Pharmaceutical Group Co., Ltd.

Market Cap 20.11B 2.99B 2.56B 2.4B 2.2B 4.12B 286B 4.17B 28.33B 11.05B 144B 11.23B 10.99B 476B P/E 2026 *
13.5x
P/E 2027 * 11.7x
Enterprise Value 16.59B 2.47B 2.11B 1.98B 1.81B 3.4B 236B 3.44B 23.37B 9.11B 119B 9.27B 9.07B 392B EV / Sales 2026 *
0.55x
EV / Sales 2027 * 0.49x
Free-Float
34.77%
Yield 2026 *
5.1%
Yield 2027 * 5.62%
Apr. 24 Dashenlin Pharma's Q1 Profit Rises 11% MT
Apr. 24 Dashenlin Pharma's 2025 Profit Jumps 35%, Revenue Rises 4% MT
Apr. 23 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
Apr. 23 Dashenlin pharmaceutical 2025 net profit up 35.0% y/y RE
Apr. 22 Sipai Health to Sell Stake in Pharmacy Operator to Dashenlin Pharmaceutical For RMB 51.7 Million MT
Apr. 22 DaShenLin Pharmaceutical Group Co., Ltd. signed a equity transfer agreement to acquire Sipai Zhihe Technology Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million. CI
25-10-29 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-08-28 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-04-25 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-04-25 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
24-10-15 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024 CI
24-09-19 Tranche Update on DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on May 7, 2024. CI
24-09-17 DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on May 7, 2024, has closed with 6,722,254 shares, representing 0.59% for CNY 100.72 million. CI
1 day-2.91%
1 week-1.40%
Current month-6.31%
1 month-6.61%
3 months+1.44%
6 months-8.12%
Current year+0.23%
1 week 17.51
Extreme 17.51
18.34
1 month 17.41
Extreme 17.41
19.99
Current year 14.39
Extreme 14.39
21.78
1 year 14.39
Extreme 14.39
21.78
3 years 11.92
Extreme 11.92
27.89
5 years 11.92
Extreme 11.92
39.47
10 years 11
Extreme 11.002785
61.63
Manager TitleAgeSince
Chief Executive Officer 44 2019-02-27
Director of Finance/CFO 44 2018-05-09
Human Resources Officer 48 -
Director TitleAgeSince
Director/Board Member 63 2016-08-07
Chairman 59 2013-07-15
Chairman 48 2015-05-27
Change 5-day change 1-year change 3-year change Capi.($)
-2.91%-1.40%+2.26%-36.86% 2.99B
+1.63%-2.13%-40.02%-6.39% 15.73B
0.00%+0.46%-40.83%-23.83% 6.72B
+0.49%+2.25%-18.13%-12.75% 6.36B
-0.83%-0.42%-2.29%-23.01% 4.32B
+0.65%-1.99%-18.04%-38.82% 3.24B
+2.09%-0.75%-45.36%-24.10% 3.05B
-1.97%-3.96%-15.32%-7.12% 2.55B
+1.20%-1.30%+44.28% - 2.4B
-1.59%-3.33%-15.45%+18.46% 1.55B
Average -0.12%-1.11%-14.89%-17.16% 4.89B
Weighted average by Cap. +0.42%-0.91%-24.04%-15.92%

Financials

2026 *2027 *
Net sales 29.91B 4.45B 3.81B 3.57B 3.26B 6.13B 426B 6.21B 42.13B 16.43B 214B 16.7B 16.34B 707B 33.03B 4.91B 4.21B 3.94B 3.61B 6.77B 470B 6.86B 46.53B 18.15B 236B 18.45B 18.05B 781B
Net income 1.48B 221M 189M 177M 162M 304M 21.13B 308M 2.09B 816M 10.61B 829M 811M 35.11B 1.71B 255M 218M 204M 187M 351M 24.4B 356M 2.42B 942M 12.26B 958M 937M 40.55B
Net Debt -3.52B -523M -448M -420M -384M -721M -50.09B -730M -4.96B -1.93B -25.16B -1.97B -1.92B -83.22B -4.01B -596M -511M -478M -438M -821M -57.07B -832M -5.65B -2.2B -28.67B -2.24B -2.19B -94.83B
Logo DaShenLin Pharmaceutical Group Co., Ltd.
DaShenLin Pharmaceutical Group Co Ltd is a China-based company principally engaged in the pharmaceutical retailing business. The Company is mainly engaged in the chain retail business of Chinese and Western patent medicines, ginseng and antler tonic medicinal materials and Chinese herbal medicine slices, health products, medical devices and other commodities. The Company is also involved in the production of Chinese herbal medicine slices, ginseng and antler tonic, health products, Chinese and Western patent medicines. The Company's brands include Dong Zi Yun Xuan, Cocoking, Nobe Huale, Dongteng Ejiao, and Fuer. The Company mainly conducts business within domestic market.
Employees
41,141
Date Price Change Volume
26-08-21 CN¥17.66 -2.91% 5,848,260
26-08-20 CN¥18.19 +1.56% 4,978,795
26-08-19 CN¥17.91 0.00% 5,882,228
26-08-18 CN¥17.91 +0.79% 5,725,320
26-08-17 CN¥17.77 -0.78% 7,965,480
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
17.66CNY
Average target price
24.70CNY
Spread / Average Target
+39.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 603233 Stock